Developer docs
API playgroundTry for free, no card

Search company profiles

Arbor Pharmaceuticals

Full company profile

uuid0037psv

Namestring
Arbor Pharmaceuticals
Websiteurl
arborpharma.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 and headquartered in the United States (Atlanta, GA), focused on developing and commercializing difficult-to-formulate medicines for overlooked patient populations — particularly pediatric, geriatric, and institutional patients. The company's core capability is specialized formulation technology, enabling liquid, customized-dose, and otherwise hard-to-manufacture drug products across therapeutic categories including central nervous system, cardiovascular, anti-infective, oncology, endocrinology, and gastrointestinal. The product portfolio spans 50+ medicines across 10 dosage forms and 10 therapeutic areas, with a global footprint reaching over 50 countries.

The business operates a traditional specialty pharma go-to-market: an enterprise field-sales force calling on institutional healthcare facilities (hospitals, nursing homes, assisted living facilities) supplemented by retail pharmacy distribution channels in the U.S. Revenue is generated through prescription pharmaceutical sales under negotiated contracts with institutional buyers and healthcare providers, with pricing not publicly disclosed. Recent strategic activity indicates active portfolio expansion, including the 2026 acquisition of CONTRAVE for obesity/weight management, FDA approval of Aprepitant Injectable Emulsion in oncology supportive care, and prior acquisitions such as XenoPort (2016) in CNS.

The company is backed by institutional healthcare-focused investors including KKR (2014) and Signet Healthcare Partners (2010), and is led by Chairman Jason Wild and President & CEO Ed Schutter. The company describes a "Next-Gen Commercial Model" leveraging data, analytics, and AI-driven digital tools for stakeholder engagement, though evidence of deep proprietary AI capability is limited.

Short descriptiontext

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 that develops and commercializes difficult-to-formulate medicines for pediatric, geriatric, and institutional patient populations across 50+ countries and 10 therapeutic areas.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAtlanta, United States
HQ citystring
Atlanta
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, pediatric drug formulations, institutional pharmaceutical sales, prescription drug manufacturing, geriatric medicine formulations
Industry4 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Pharmaceutical Sales
TypeOne Time License
Description

Sale of prescription medications to institutional and retail customers in the U.S. market, including hospitals, nursing homes, assisted living facilities, and retail pharmacy channels.

azurity.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arbor Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells prescription drug products for pediatric, geriatric, and institutional patient populations. Its portfolio focuses on difficult-to-formulate medicines — including liquid and customized-dose forms — across central nervous system, cardiovascular, anti-infective, and oncologic therapeutic areas, sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels in the U.S.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Specialty Prescription Pharmaceutical Portfolio
CategorySpecialty Pharmaceuticals
Description

A portfolio of prescription drug products in difficult-to-formulate formats (including liquid and customized-dose forms) sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels for use in pediatric, geriatric, and institutional patient populations with specialized medication needs.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ANI is a U.S. specialty pharmaceuticals company that acquires, develops, and markets branded and generic prescription drugs across multiple therapeutic areas, with a comparable focus on niche patient populations and institutional channels.

TypeDirect peer
Description

Amneal combines specialty, branded, and complex generics with a broad therapeutic portfolio and manufacturing capabilities, mirroring Arbor's mid-sized U.S. specialty pharma profile and product-acquisition strategy.

TypeDirect peer
Description

Mallinckrodt is a specialty pharmaceutical company focused on difficult-to-manufacture branded and specialty generic products across CNS, autoimmune, and hospital channels — closely aligned with Arbor's specialty/institutional focus.

TypeDirect peer
Description

Upsher-Smith is a U.S. specialty pharma marketing branded and generic prescription products across CNS, dermatology, and women's health — a similar mid-sized, vertically focused portfolio to Arbor's.

5Padagis
TypeDirect peer
Description

Padagis is a specialty pharmaceuticals company focused on complex generics, dermatology, and OTC products, providing a direct comparison for Arbor's difficult-to-formulate, niche-prescription business model.

TypeDirect peer
Description

Endo is a specialty pharma with a diversified portfolio spanning sterile injectables, generics, and branded specialty products, often used as a comparable for Arbor's mid-cap specialty franchise economics.

TypeBroad incumbent
Description

Perrigo is a large specialty and consumer-focused pharma with significant U.S. prescription and OTC exposure, providing a broader-market comparable for Arbor's institutional and retail channels.

TypeDirect peer
Description

Azurity is a privately held specialty pharma delivering innovative medicines for overlooked patients across 50+ countries and 10 therapeutic areas — closely matching Arbor's product portfolio, mission, and institutional GTM described in the source data.

TypeDirect peer
Description

Jazz is a specialty pharma company focused on CNS and oncology products, with comparable institutional sales infrastructure and a similar strategy of acquiring and developing differentiated specialty therapeutics.

TypeBroad incumbent
Description

Bausch Health operates a much larger specialty pharma and consumer health portfolio, but its branded specialty division competes in overlapping therapeutic categories with Arbor and is a comparable for specialty pharma scale dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arbor Pharmaceuticals

Specialty Pharmaceuticalsarborpharma.com

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 that develops and commercializes difficult-to-formulate medicines for pediatric, geriatric, and institutional patient populations across 50+ countries and 10 therapeutic areas.

What Arbor Pharmaceuticals does

Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 and headquartered in the United States (Atlanta, GA), focused on developing and commercializing difficult-to-formulate medicines for overlooked patient populations — particularly pediatric, geriatric, and institutional patients. The company's core capability is specialized formulation technology, enabling liquid, customized-dose, and otherwise hard-to-manufacture drug products across therapeutic categories including central nervous system, cardiovascular, anti-infective, oncology, endocrinology, and gastrointestinal. The product portfolio spans 50+ medicines across 10 dosage forms and 10 therapeutic areas, with a global footprint reaching over 50 countries.

The business operates a traditional specialty pharma go-to-market: an enterprise field-sales force calling on institutional healthcare facilities (hospitals, nursing homes, assisted living facilities) supplemented by retail pharmacy distribution channels in the U.S. Revenue is generated through prescription pharmaceutical sales under negotiated contracts with institutional buyers and healthcare providers, with pricing not publicly disclosed. Recent strategic activity indicates active portfolio expansion, including the 2026 acquisition of CONTRAVE for obesity/weight management, FDA approval of Aprepitant Injectable Emulsion in oncology supportive care, and prior acquisitions such as XenoPort (2016) in CNS.

The company is backed by institutional healthcare-focused investors including KKR (2014) and Signet Healthcare Partners (2010), and is led by Chairman Jason Wild and President & CEO Ed Schutter. The company describes a "Next-Gen Commercial Model" leveraging data, analytics, and AI-driven digital tools for stakeholder engagement, though evidence of deep proprietary AI capability is limited.

Arbor Pharmaceuticals firmographics

Firmographics
Name
Arbor Pharmaceuticals
Website
https://arborpharma.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
51–100 employees
Short description
Arbor Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006 that develops and commercializes difficult-to-formulate medicines for pediatric, geriatric, and institutional patient populations across 50+ countries and 10 therapeutic areas.
Ownership category
akta.pro rank

Arbor Pharmaceuticals industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Pediatric drug formulations
  • Institutional pharmaceutical sales
  • Prescription drug manufacturing
  • Geriatric medicine formulations

Where Arbor Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Atlanta
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arbor Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Prescription Pharmaceutical Sales: Sale of prescription medications to institutional and retail customers in the U.S. market, including hospitals, nursing homes, assisted living facilities, and retail pharmacy channels.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Arbor Pharmaceuticals product offering

Product offering

Core offering

Arbor Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells prescription drug products for pediatric, geriatric, and institutional patient populations. Its portfolio focuses on difficult-to-formulate medicines — including liquid and customized-dose forms — across central nervous system, cardiovascular, anti-infective, and oncologic therapeutic areas, sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels in the U.S.

Differentiator

Problem solved

Functional benefit

Products and services

  • Specialty Prescription Pharmaceutical Portfolio A portfolio of prescription drug products in difficult-to-formulate formats (including liquid and customized-dose forms) sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels for use in pediatric, geriatric, and institutional patient populations with specialized medication needs.

Companies that use Arbor Pharmaceuticals

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Arbor Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Arbor Pharmaceuticals partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Arbor Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • ANI Pharmaceuticals: ANI is a U.S. specialty pharmaceuticals company that acquires, develops, and markets branded and generic prescription drugs across multiple therapeutic areas, with a comparable focus on niche patient populations and institutional channels.
  • Amneal Pharmaceuticals: Amneal combines specialty, branded, and complex generics with a broad therapeutic portfolio and manufacturing capabilities, mirroring Arbor's mid-sized U.S. specialty pharma profile and product-acquisition strategy.
  • Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharmaceutical company focused on difficult-to-manufacture branded and specialty generic products across CNS, autoimmune, and hospital channels — closely aligned with Arbor's specialty/institutional focus.
  • Upsher-Smith Laboratories: Upsher-Smith is a U.S. specialty pharma marketing branded and generic prescription products across CNS, dermatology, and women's health — a similar mid-sized, vertically focused portfolio to Arbor's.
  • Padagis: Padagis is a specialty pharmaceuticals company focused on complex generics, dermatology, and OTC products, providing a direct comparison for Arbor's difficult-to-formulate, niche-prescription business model.
  • Endo Pharmaceuticals: Endo is a specialty pharma with a diversified portfolio spanning sterile injectables, generics, and branded specialty products, often used as a comparable for Arbor's mid-cap specialty franchise economics.
  • Azurity Pharmaceuticals: Azurity is a privately held specialty pharma delivering innovative medicines for overlooked patients across 50+ countries and 10 therapeutic areas — closely matching Arbor's product portfolio, mission, and institutional GTM described in the source data.
  • Jazz Pharmaceuticals: Jazz is a specialty pharma company focused on CNS and oncology products, with comparable institutional sales infrastructure and a similar strategy of acquiring and developing differentiated specialty therapeutics.

Broad incumbents

  • Perrigo Company: Perrigo is a large specialty and consumer-focused pharma with significant U.S. prescription and OTC exposure, providing a broader-market comparable for Arbor's institutional and retail channels.
  • Bausch Health Companies: Bausch Health operates a much larger specialty pharma and consumer health portfolio, but its branded specialty division competes in overlapping therapeutic categories with Arbor and is a comparable for specialty pharma scale dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Arbor Pharmaceuticals social profiles

Digital presence

Arbor Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arbor Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles6 records

Arbor Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arbor Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arbor Pharmaceuticals

What does Arbor Pharmaceuticals do?

Arbor Pharmaceuticals is a specialty pharmaceutical company that develops, manufactures, and sells prescription drug products for pediatric, geriatric, and institutional patient populations. Its portfolio focuses on difficult-to-formulate medicines — including liquid and customized-dose forms — across central nervous system, cardiovascular, anti-infective, and oncologic therapeutic areas, sold to hospitals, nursing homes, assisted living facilities, and retail pharmacy channels in the U.S.

Is Arbor Pharmaceuticals a public or private company?

Arbor Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.

When was Arbor Pharmaceuticals founded?

Arbor Pharmaceuticals was founded in 2006. It employs 51 to 100 people.

Where is Arbor Pharmaceuticals based?

Arbor Pharmaceuticals is headquartered in Atlanta, United States, in the North America region.

How does Arbor Pharmaceuticals make money?

One revenue line is on record: prescription Pharmaceutical Sales.

Who are Arbor Pharmaceuticals's main competitors?

Direct peers on record are ANI Pharmaceuticals, Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Padagis, Endo Pharmaceuticals, Azurity Pharmaceuticals and Jazz Pharmaceuticals. Broad incumbents are Perrigo Company and Bausch Health Companies.

Does Arbor Pharmaceuticals have an API?

No public API is recorded for Arbor Pharmaceuticals.

What industry is Arbor Pharmaceuticals in?

Arbor Pharmaceuticals's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Alternatives WatchNovaQuest's Azurity Pharma acquires Arbor Pharma from KKR, othersAzurity Pharmaceuticals agreed to acquire Arbor Pharmaceuticals from investors including KKR and JW Asset Management. The deal adds 15 FDA-approved specialty products to Azurity's portfolio, bringing over 30 commercialized products. Arbor had raised at least $40.4 million, with NovaQuest Capital remaining the majority owner.Business Wire BlogAzurity Pharmaceuticals to Acquire and Merge with Arbor PharmaceuticalsAzurity Pharmaceuticals agreed to acquire Arbor Pharmaceuticals from existing investors, including JW Asset Management and KKR, and merge the companies. Financial terms were not disclosed, and the deal is expected to close in September pending regulatory approvals. The combined company will operate as Azurity with a portfolio of over 30 commercialized products.Azurity PharmaceuticalsAzurity Pharmaceuticals to Acquire and Merge with Arbor PharmaceuticalsAzurity Pharmaceuticals has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors JW Asset Management and KKR, with NovaQuest Private Equity supporting the combined entity. The merger will create a leading specialty pharmaceutical company focused on innovative products for underserved patient conditions, pending regulatory approvals expected by September 2021. Financial details of the transaction were not disclosed.PR NewswireFDA Approves Lotion for Nonprescription Use to Treat Head LiceThe FDA approved Sklice (ivermectin) lotion, 0.5% for nonprescription use through a prescription-to-OTC switch, granting approval to Arbor Pharmaceuticals LLC. The drug, originally approved as a prescription treatment in February 2012 for head lice in patients 6 months and older, will now be marketed in the United States as an over-the-counter product. The approval aims to increase consumer access to effective topical head lice treatment, with the CDC estimating 6 to 12 million cases annually in children aged 3 to 11.PR NewswireArbor Presents Data from Pivotal Study of AR19, an Investigational ADHD Prescription Stimulant Treatment Specifically Designed to Resist Physical Manipulation for Nonmedical Misuse or AbuseArbor Pharmaceuticals announced positive safety and efficacy results from a pivotal Phase 3 study of AR19, its investigational immediate-release amphetamine sulfate capsule for ADHD treatment, in 320 adults aged 18 to 55. Both tested doses (20 mg and 40 mg) met the primary efficacy endpoint, demonstrating statistically significant symptom improvement on the Adult ADHD Investigator Symptom Rating Scale (AISRS) compared to placebo (each P<0.001). The drug, currently under FDA review with a PDUFA target action date of November 15, 2020, is specifically designed to resist manipulation for non-oral misuse such as snorting, smoking, or injecting.PR NewswireArbor Pharmaceuticals, LLC Confirms Availability of Triptodur® (triptorelin) for Patients with Central Precocious PubertyArbor Pharmaceuticals, LLC confirmed full availability of Triptodur® (triptorelin) for pediatric patients with central precocious puberty, stating it has ample supply and has ordered additional product from its manufacturing partner Debiopharm in response to reported industry shortages of a competing injection product. Triptodur, the first FDA-approved twice-yearly injectable GnRHa for CPP, has been on the market for over two years with thousands of prescriptions filled and is manufactured by Debiopharm in Switzerland.PR NewswireShaquille O'Neal to Address Heart Failure Awareness Among African Americans During Keynote Presentation at 23rd HFSA Annual Scientific MeetingThe Heart Failure Society of America announced that basketball legend Shaquille O'Neal will deliver a keynote address at the 23rd HFSA Annual Scientific Meeting in Philadelphia on September 16, 2019, focusing on heart failure awareness in the African American community. Research cited in the announcement indicates African Americans may be up to 20 times more likely than white Americans to develop heart failure before age 50. O'Neal partnered with Arbor Pharmaceuticals in March 2019 to launch the 'Shaquille Gets Real About Heart Failure' national initiative aimed at addressing this disparity.PR NewswireArbor Pharmaceuticals Teams Up with Shaquille O'Neal to Help African Americans 'Get Real' About Heart FailureArbor Pharmaceuticals announced the launch of the Shaquille Gets Real About Heart Failure campaign, a national educational initiative partnering with Basketball Hall of Famer Shaquille O'Neal to raise awareness about heart failure disparities in African Americans. The campaign promotes BiDil, the first FDA-approved heart failure medication specifically indicated for self-identified African American patients, which clinical trials showed reduced mortality risk by 43 percent and first hospitalization by 39 percent. The initiative includes a dedicated website, educational video series, and the Shaq BiDil Access Program to improve medication access.PR NewswireNon-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025ReportLinker released a market analysis report titled "Non-Opioid Drugs for Chronic Pain and Pain Management Devices Market, 2018-2025," detailing the development landscape of non-addictive therapeutics and devices. The report highlights that over 145 non-opioid product candidates are in various stages of development to address the unmet needs caused by the opioid crisis, with the market projected to grow at an annualized rate of approximately 40% through 2025. It also profiles key industry players, including established pharmaceutical companies like Arbor Pharmaceuticals and Horizon Pharma, and device developers such as Medtronic and Boston Scientific.PR NewswireArbor Pharmaceuticals, LLC y Debiopharm International SA anuncian la disponibilidad en el mercado de Triptodur™, formulación de triptorelina 6 meses para tratamiento de la Pubertad Precoz Central (PPCArbor Pharmaceuticals, LLC and Debiopharm International SA announced that Triptodur™ (triptorelin) 6-month formulation is now available for sale in the United States for the treatment of Central Precocious Puberty (CPP) in pediatric patients from age 2. The drug, developed by Debiopharm and manufactured in Switzerland by Debiopharm Research & Manufacturing SA, is the first GnRH agonist administered via intramuscular injection with a six-month dosing interval, having received FDA approval in June 2017. In Phase III clinical trials, 93% of patients achieved prepubertal LH levels after 6 months of treatment, rising to 98% after 12 months.